{"transactions":[{"id":708295,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-07-16T21:39:50.000Z","date":"2026-07-14","kind":"exercise","planned":true,"acquired":false,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027."}],"balance_after":48750,"derivative":{"exercise_price":3.04,"exercise_date":"2026-06-30","expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001133416-26-000063","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000063/form4.xml","form_type":"4"}},{"id":708294,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-16T21:39:50.000Z","date":"2026-07-14","kind":"sale","planned":true,"acquired":false,"shares":16250,"price":5.1252,"value":83284.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000063/form4.xml","form_type":"4"}},{"id":708293,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-16T21:39:50.000Z","date":"2026-07-14","kind":"exercise","planned":true,"acquired":true,"shares":16250,"price":3.04,"value":49400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0001133416-26-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000063/form4.xml","form_type":"4"}},{"id":723046,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":47467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":2.5,"exercise_date":"2025-07-31","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":47467},"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723045,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":2533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025."}],"balance_after":47467,"derivative":{"exercise_price":2.5,"exercise_date":"2025-04-30","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":2533},"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723044,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":2037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027."}],"balance_after":100000,"derivative":{"exercise_price":2.2,"exercise_date":"2025-03-11","expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":2037},"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723043,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":47467,"price":5.04,"value":239233.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723042,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":47467,"price":2.5,"value":118667.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":47467,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723041,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":2533,"price":5,"value":12665.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723040,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":2533,"price":2.5,"value":6332.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":2533,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723039,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":2037,"price":5,"value":10185.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":723038,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T23:23:14.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":2037,"price":2.2,"value":4481.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":2037,"source":{"system":"sec-edgar","filing":"0001133416-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000059/form4.xml","form_type":"4"}},{"id":726731,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-06-25T20:06:15.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":7557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":32500,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":7557},"source":{"system":"sec-edgar","filing":"0001133416-26-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000057/form4.xml","form_type":"4"}},{"id":726730,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:06:15.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":7557,"price":3.14,"value":23728.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000057/form4.xml","form_type":"4"}},{"id":726729,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:06:15.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":7557,"price":1.23,"value":9295.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":7557,"source":{"system":"sec-edgar","filing":"0001133416-26-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000057/form4.xml","form_type":"4"}},{"id":760565,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-05-28T13:13:05.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":false,"shares":568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 16,250  on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":40057,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":568},"source":{"system":"sec-edgar","filing":"0001133416-26-000055","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000055/form4.xml","form_type":"4"}},{"id":760564,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-28T13:13:05.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":568,"price":3.1004,"value":1761.0272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000055/form4.xml","form_type":"4"}},{"id":760563,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-28T13:13:05.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":true,"shares":568,"price":1.23,"value":698.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026"}],"balance_after":568,"source":{"system":"sec-edgar","filing":"0001133416-26-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000055/form4.xml","form_type":"4"}},{"id":934510,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:50:15.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001133416-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000038/form4.xml","form_type":"4"}},{"id":934509,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:50:15.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":65000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-26-000038","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000038/form4.xml","form_type":"4"}},{"id":947577,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2026-01-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947576,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":21446,"price":3.6466,"value":78204.9836,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947575,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":25499,"price":3.8985,"value":99407.8515,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":21446,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947574,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":13055,"price":4.1968,"value":54789.224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":46945,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":947573,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:53:32.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001133416-26-000004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000004/form4.xml","form_type":"4"}},{"id":952675,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:07:55.000Z","date":"2025-12-31","kind":"exercise","planned":true,"acquired":false,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 16,250  on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":40625,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001133416-26-000002","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000002/form4.xml","form_type":"4"}},{"id":952674,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:07:55.000Z","date":"2025-12-31","kind":"sale","planned":true,"acquired":false,"shares":8125,"price":4.0725,"value":33089.0625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.15. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-26-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000002/form4.xml","form_type":"4"}},{"id":952673,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:07:55.000Z","date":"2025-12-31","kind":"exercise","planned":true,"acquired":true,"shares":8125,"price":1.23,"value":9993.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":8125,"source":{"system":"sec-edgar","filing":"0001133416-26-000002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000002/form4.xml","form_type":"4"}},{"id":962321,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025."}],"balance_after":50000,"derivative":{"exercise_price":2.5,"exercise_date":"2025-07-31","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962320,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":6463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027."}],"balance_after":102037,"derivative":{"exercise_price":2.2,"exercise_date":"2025-03-31","expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":6364},"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962319,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":7.04,"value":59840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962318,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":2.5,"value":21250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962317,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":6463,"price":7.04,"value":45499.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962316,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":6463,"price":2.2,"value":14218.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":6463,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":962315,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:06:14.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":4479,"price":7.04,"value":31532.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001133416-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000069/form4.xml","form_type":"4"}},{"id":999238,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":false,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."}],"balance_after":48750,"derivative":{"exercise_price":1.23,"exercise_date":"2025-06-30","expiration_date":"2035-01-23","underlying":"Common stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999237,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":false,"shares":41500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025."}],"balance_after":58500,"derivative":{"exercise_price":2.5,"exercise_date":"2025-07-31","expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":41500},"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999236,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":false,"shares":41500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027."}],"balance_after":108500,"derivative":{"exercise_price":2.2,"exercise_date":"2025-03-31","expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":41500},"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999235,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":16250,"price":5.47,"value":88887.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":4479,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999234,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":true,"shares":16250,"price":1.23,"value":19987.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":20729,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999233,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":41500,"price":5.47,"value":227005.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":4479,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999232,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":true,"shares":41500,"price":2.5,"value":103750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":45979,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999231,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":41500,"price":5.47,"value":227005.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":4479,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999230,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":true,"shares":41500,"price":2.2,"value":91300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":45979,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":999229,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-14T21:02:02.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":21867,"price":5.47,"value":119612.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":4479,"source":{"system":"sec-edgar","filing":"0001133416-25-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000054/form4.xml","form_type":"4"}},{"id":1294684,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-27T21:05:41.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-25-000012","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000012/form4.xml","form_type":"4"}},{"id":1294683,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:05:41.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026."}],"balance_after":65000,"derivative":{"exercise_price":1.23,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-25-000012","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000012/form4.xml","form_type":"4"}},{"id":1322072,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-26T13:20:02.000Z","date":"2024-12-23","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-24-000072","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000072/form4.xml","form_type":"4"}},{"id":1322071,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-26T13:20:02.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":13654,"price":0.8821,"value":12044.1934,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares of common stock sold pursuant to previously disclosed 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Multiple transactions ranging from $0.92 to $0.85 with an average of $0.8821."}],"balance_after":26346,"source":{"system":"sec-edgar","filing":"0001133416-24-000072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000072/form4.xml","form_type":"4"}},{"id":1322070,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-26T13:20:02.000Z","date":"2024-12-23","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001133416-24-000072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000072/form4.xml","form_type":"4"}},{"id":1441136,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-08-05T12:41:21.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001133416-24-000052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000052/form4.xml","form_type":"4"}},{"id":1441135,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":30139,"kind":"person","name":"Jamil Khurram","position":1,"cik":"0002032345","reported_name":"Jamil Khurram","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-05T12:41:21.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of October 31, 2024; January 31, 2025; April 30, 2025; and July 31, 2025."}],"balance_after":100000,"derivative":{"exercise_price":2.5,"expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001133416-24-000052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000052/form4.xml","form_type":"4"}}]}